■炭疽芽孢杆菌分泌包含保护性抗原(PA)的三方毒素,水肿因子(EF),和致死因子(LF)。人类炭疽疫苗主要由炭疽保护性抗原(PA)组成。由于商业炭疽疫苗(人/兽医)的使用与若干限制相关,因此正在进行相当多的努力来提高疫苗的效力。
■在这项研究中,称为ELP的三重嵌合抗原(基因登录号:MT590758),包含PA的高免疫原性结构域,LF,EF是设计的,constructed,并评估豚鼠模型对炭疽的免疫能力。
■考虑抗原滴定和免疫方案进行免疫。在豚鼠中评估了ELP的免疫保护功效,并使用炭疽芽孢杆菌17JB菌株孢子的攻击测试将其与兽用炭疽疫苗的效力进行了比较。
■结果表明ELP抗原诱导强体液应答。发现ELP的T细胞反应与PA相似,并显示ELP可以保护100%,100%,100%,80%和60%的动物从50、70、90、100和120倍的最小致死剂量(MLD,等于5×105孢子/毫升),分别,在48小时内杀死对照动物。
■可以得出结论,ELP抗原具有针对炭疽的适当免疫的必要要求,可以用于开发针对炭疽的有效重组疫苗候选物。
UNASSIGNED: Bacillus anthracis secretes a tripartite toxin comprising protective antigen (PA), edema factor (EF), and lethal factor (LF). The human anthrax vaccine is mainly composed of the anthrax protective antigen (PA). Considerable efforts are being directed towards improving the efficacy of vaccines because the use of commercial anthrax vaccines (human/veterinary) is associated with several limitations.
UNASSIGNED: In this study, a triple chimeric antigen referred to as ELP (gene accession no: MT590758) comprising highly immunogenic domains of PA, LF, and EF was designed, constructed, and assessed for the immunization capacity against anthrax in a guinea pig model.
UNASSIGNED: Immunization was carried out considering antigen titration and immunization protocol. The immunoprotective efficacy of the ELP was evaluated in guinea pigs and compared with the potency of veterinary anthrax vaccine using a challenge test with B. anthracis 17JB strain spores.
UNASSIGNED: The results demonstrated that the ELP antigen induced strong humoral responses. The T-cell response of the ELP was found to be similar to PA, and showed that the ELP could protect 100%, 100%, 100%, 80% and 60% of the animals from 50, 70, 90, 100 and 120 times the minimum lethal dose (MLD, equal 5 × 105 spore/ml), respectively, which killed control animals within 48 h.
UNASSIGNED: It is concluded that the ELP antigen has the necessary requirement for proper immunization against anthrax and it can be used to develop an effective recombinant vaccine candidate against anthrax.